Reenie McCarthy is the Chief Executive Officer and a member of the Board of Stealth BioTherapeutics. As a 20+ year veteran of the investment team and head of the Boston office for Morningside, Stealth’s principal investor, Reenie has extensive experience working with numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic focus and providing operational and management oversight to venture-backed technology companies. Reenie was a director of Biovex, prior to its sale to Amgen, and of Tile Shop, prior to its NASDAQ listing. Reenie has worked on financings for Sohu.com and Morningside TMT Fund, an early investor in Xiaomi and Xunlei. Reenie’s current board seats in addition to Stealth include DNAtrix, CellCentric, Cognoa, Incarda, Excera, Ground Signal, Clean Membranes and Freight Farms. Prior to joining Morningside, Reenie spent five years as a corporate lawyer with Richards & O’Neil in New York City, working on corporate mergers and acquisitions, employment matters, and pharmaceutical licensing and technology transfer matters. Reenie received her BA, cum laude, from Bates College and her JD from the University of Pennsylvania Law School.